Research & Development
Bile Duct Cancer
FDA clears FoundationOne CDx as test for bile duct cancer drug
FoundationOne CDx is the first and only FDA-approved companion diagnostic for cholangiocarcinoma. It was previously been cleared for guiding use of 20 other different therapies across multiple cancer types, the firm noted.
April 19, 2020
Machine learning helps liquid biopsy detect cancer based on DNA
Researchers from the university's Johns Hopkins Kimmel Cancer Center have conducted a proof-of-concept study of the test, called DNA evaluation of fragments for early interception (DELFI). The study found that the DELFI technology accurately detected cancer DNA in 57% to 99% of blood samples from 208 patients who had cancers of the breast, colon and rectum, lung, ovaries, pancreas, or bile ducts.
May 28, 2019
Page 1 of 1